You are here


Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers

Primary tabs

The National Cancer Institute (NCI) seeks research and co-development partners and/or licensees for chimeric antigen receptors (CARs) targeting the B-cell antigen CD22
NIH Reference Number
Product Type
  • Chimeric Antigen Receptors (CARs), CD22, Chronic Lymphocytic Leukemia, CLL, Hairy Cell Leukemia, HCL, Pediatric, Acute Lymphoblastic Leukemia, ALL, Immunotherapy, B-cell, Adoptive Cell Therapy, Dimitrov
Collaboration Opportunity
This invention is available for licensing and co-development.
Description of Technology

Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.  Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.  Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction.  This promising new therapeutic approach is known as adoptive cell therapy.
CD22 is a cell surface protein expressed on a large number of B-cell lineage hematological cancers, such as leukemia and lymphoma.  Several promising therapies are being developed which target CD22, including therapeutic antibodies and immunotoxins.  This technology concerns the use of a high affinity antibody binding fragment to CD22 (known as m971), as the targeting moiety of a CAR. The resulting CAR can be used in adoptive cell therapy treatment for cancer.

Potential Commercial Applications
  • Treatment of diseases associated with increased or preferential expression of CD22
  • Hematological cancers such as chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) and pediatric acute lymphoblastic leukemia (ALL)


Competitive Advantages
  • High affinity of the m971 antibody binding fragment increases the likelihood of successful targeting
  • Targeted therapy decreases non-specific killing of healthy, essential cells, potentially resulting in fewer non-specific side-effects and healthier patients
  • Hematological cancers are susceptible to cytotoxic T-cells for treating because they are present in the bloodstream 
  • Expression of CD22 only on mature cells avoids stem cell elimination during treatment



Rimas Orentas Ph.D. (NCI), Ira Pastan MD, PHD (NCI), Crystal Mackall M.D. (NCI), Dimiter Dimitrov Ph.D (NCI)

Development Stage

Shah NN et. al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial  [PMID 32286905]

Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 61/717,960 , Filed 24 Oct 2012
  • PCT: PCT Application Number PCT/US2013/060332 , Filed 25 Oct 2018
  • Foreign Issued: Australian - Patent Number 2013335180, Issued 25 Oct 2018
  • Foreign Issued: Australian - Patent Number 2018204257, Issued 18 Jun 2020
  • Foreign Filed: Brazil - Patent Application BR112015009003-6, Filed 22 Apr 2015
  • Foreign Filed: Canadian - Patent Application 2889055
  • Foreign Issued: Chinese - Patent Number ZL 201380061387.5, Issued 12 Jul 2019
  • Foreign Filed: - Patent Application 201910500128.7, Filed 11 Jun 2019
  • Foreign Issued: European - Patent Number 2912061, Issued 06 Feb 2019
  • Foreign Issued: German - Patent Number 2912061, Issued 06 Feb 2019
  • Foreign Issued: Spain - Patent Number 2912061, Issued 06 Feb 2019
  • Foreign Issued: France - Patent Number 2912061, Issued 06 Feb 2019
  • Foreign Issued: United Kingdom - Patent Number 2912061, Issued 06 Feb 2019
  • Foreign Issued: Italy - Patent Number 2912061, Issued 18 Feb 2019
  • Foreign Filed: Indian - Patent Application
  • Foreign Issued: Japanese - Patent Number 6338252, Issued 18 May 2018
  • Foreign Filed: Japanese - Patent Application
  • Foreign Issued: Russian - Patent Number 2658485, Filed 21 Jun 2018
  • Foreign Filed: Russian - Patent Application
  • U.S. Patent Issued: U.S. Patent Number 10,072,078, Issued 11 Sep 2018
  • U.S. Patent Issued: U.S. Patent Number 10,703,816, Issued 07 Jul 2020
  • U.S. Patent Filed: U.S. Patent Application Number 16/869,792, Filed 08 May 2020
  • Foreign Issued: Hong Kong - Patent Number HK1213922, Issued 20 Mar 2020
Therapeutic Area
Wednesday, June 2, 2021